Aurobindo Pharma's Subsidiary Receives USFDA's OAI Classification Post Inspection
Synopsis
Aurobindo Pharma's subsidiary has been classified as 'Official Action Indicated' by the USFDA after a recent inspection. Despite this, the company continues to report strong financial performance and remains committed to high manufacturing standards.
Key Takeaways
Aurobindo Pharma's subsidiary received an OAI classification from the USFDA.
The inspection revealed nine observations leading to the Form 483.
Despite regulatory scrutiny, the company continues to report strong financial performance .
Net profit increased by 7.5% year-on-year .
Aurobindo remains committed to high manufacturing standards .
New Delhi, March 17 (NationPress) - Aurobindo Pharma announced on Tuesday that the US Food and Drug Administration (USFDA) has designated one of its subsidiary facilities as “Official Action Indicated” (OAI) following an inspection carried out last year.
According to a regulatory filing, the USFDA scrutinized Unit-II of Eugia Pharma Specialities Limited, a wholly-owned subsidiary of Aurobindo, situated in Bhiwadi, Rajasthan, from November 3 to November 14, 2025.
Upon concluding the inspection, the regulator issued a Form 483 comprising nine observations.
“Upon conclusion of the inspection, a ‘Form 483’ was issued detailing nine observations,” Aurobindo Pharma stated in its exchange filing.
“The USFDA has subsequently classified the inspection status of this unit as ‘Official Action Indicated’ (OAI),” it added.
This OAI classification indicates that the regulator believes certain issues identified during the inspection may necessitate regulatory action.
Nonetheless, the company has assured that it does not anticipate any immediate ramifications on its business operations as a result of this development.
“Currently, the Company does not predict any impact on its business. We remain dedicated to upholding the highest quality manufacturing standards at all our facilities worldwide,” Aurobindo Pharma emphasized.
Aurobindo Pharma reiterated its commitment to maintaining stringent manufacturing quality standards across all its facilities and will keep exchanges updated on any further developments.
Despite this regulatory situation, the company’s financial performance has remained robust.
For the quarter ending December, Aurobindo Pharma reported a 7.5% year-on-year rise in net profit to Rs 909.8 crore, compared to Rs 846 crore during the same period last year.
This profit figure includes a one-off cost of Rs 65 crore attributed to changes in labor legislation.
Quarterly revenue increased by 8.4% year-on-year, reaching Rs 8,646 crore, up from Rs 7,979 crore a year earlier.
The company’s EBITDA also grew by 12.4% to Rs 1,773.6 crore, with the EBITDA margin improving to 20.5% from 19.8% in the same quarter last year.
Aurobindo Pharma’s shares closed 0.80% higher at Rs 1,289.80 on Tuesday, just before the announcement.
Point of View
Aurobindo Pharma's classification by the USFDA as 'Official Action Indicated' raises concerns about regulatory compliance. However, the company's strong financial results suggest resilience in their operations. It's crucial to monitor how Aurobindo navigates this situation while upholding its commitment to quality.
NationPress
7 May 2026
Frequently Asked Questions
What does the OAI status mean?
The OAI status indicates that the USFDA believes certain issues identified during the inspection may require regulatory action.
How did Aurobindo Pharma perform financially?
Aurobindo Pharma reported a 7.5% increase in net profit for the December quarter, demonstrating strong financial performance despite regulatory challenges.
Will this impact Aurobindo Pharma's operations?
The company has stated it does not expect any immediate impact on its business operations due to the OAI classification.
What were the results of the inspection?
The inspection resulted in a Form 483 being issued, which included nine observations.
Where is the inspected unit located?
The inspected unit, Unit-II of Eugia Pharma Specialities Limited, is located in Bhiwadi, Rajasthan.
